NK-92 cells expressing a FLT3-specific CAR with a CD28–CD3ζ signaling domain demonstrated strong cytolytic activity against FLT3+ B-ALL and AML cells in vitro and robust antileukemic efficacy in xenograft models. This evidence concerns the gene FLT3 and acute myeloid leukemia.